Literature DB >> 17219118

Treatment of central retinal vein occlusion by radial optic neurotomy in 107 cases.

H C Hasselbach1, F Ruefer, N Feltgen, U Schneider, S Bopp, L L Hansen, H Hoerauf, U Bartz-Schmidt, J Roider.   

Abstract

BACKGROUND: To evaluate the potential role of radial optic neurotomy (RON), a new surgical technique has been recently proposed for treating central retinal vein occlusion (CRVO). It is hypothesized that CRVO constitutes a neurovascular compartment syndrome at the site of the lamina cribrosa, which can be alleviated by performing a radial incision at the nasal part of the optic nerve head, relaxing the cribriform plate and the adjacent sclera.
METHODS: One hundred and seven patients were treated with RON for CRVO at five collaborating ophthalmologic centers. All patients were evaluated by a standardized protocol. For analysis of the angiographic and fundus findings, reference images were used. Intraoperative and postoperative complications were reviewed.
RESULTS: On 55 right and 52 left eyes of 107 patients (55.6% male, 44.4% female) with a median age of 68 years (range 21-91 years), RON was performed. The median follow-up time was 6 months (range 1-24 months). The median preoperative visual acuity (VA) was 0.05 (logMAR 1.3), increasing to a median postoperative VA of 0.08 (logMAR 1.1). Patients with an interval of more than 90 days between RON and onset of CRVO showed no significant change in VA at the 6-month follow-up. Severe peripapillary swelling of the optic nerve head prior to RON resulted in an average increase of 4.2 lines in VA at the 6-month follow-up. Angiographic findings of shunt vessels were seen in 18/30 cases after 12 months and were accompanied by an average improvement of VA of six lines. Visual field tests showed various defects in 86.8% of all cases. In one patient an iatrogenic injury of the central retinal artery occurred (0.9%).
CONCLUSION: Despite the potential risk of visual field defects, RON seems to be a quite safe procedure. The majority of patients showed rapid normalization of the morphologic fundus findings, with an improvement in VA uncommon for the natural history of CRVO. No significant change in VA was seen in patients with an interval of more than 90 days between the onset of CRVO and RON. A prospective study is warranted for further investigation.

Entities:  

Mesh:

Year:  2007        PMID: 17219118     DOI: 10.1007/s00417-006-0501-5

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.535


  27 in total

1.  Radial optic neurotomy for central retinal vein occlusion.

Authors:  Sohan Singh Hayreh
Journal:  Retina       Date:  2002-12       Impact factor: 4.256

2.  Radial optic neurotomy for central retinal vein obstruction.

Authors:  Leon A Bynoe; E Mitchel Opremcak; Robert A Bruce; Mark D Lomeo; Chet D Ridenour; Alan D Letson; Alan J Rehmar
Journal:  Retina       Date:  2002-06       Impact factor: 4.256

3.  Laser-induced chorioretinal venous anastomosis for nonischemic central retinal vein occlusion: evaluation of the complications and their risk factors.

Authors:  I L McAllister; J P Douglas; I J Constable; D Y Yu
Journal:  Am J Ophthalmol       Date:  1998-08       Impact factor: 5.258

4.  A randomised prospective study of treatment of non-ischaemic central retinal vein occlusion by isovolaemic haemodilution.

Authors:  L L Hansen; J Wiek; M Wiederholt
Journal:  Br J Ophthalmol       Date:  1989-11       Impact factor: 4.638

5.  Intravitreal tissue plasminogen activator for acute central retinal vein occlusion.

Authors:  J M Lahey; D S Fong; J Kearney
Journal:  Ophthalmic Surg Lasers       Date:  1999-06

6.  Radial optic neurotomy as treatment for central retinal vein occlusion.

Authors:  Jennifer S Weizer; Sandra S Stinnett; Sharon Fekrat
Journal:  Am J Ophthalmol       Date:  2003-11       Impact factor: 5.258

7.  Baseline and early natural history report. The Central Vein Occlusion Study.

Authors: 
Journal:  Arch Ophthalmol       Date:  1993-08

8.  Transvitreal optic neurotomy for nonarteritic anterior ischemic optic neuropathy.

Authors:  Masoud Soheilian; Arash Koochek; Shahin Yazdani; Gholam A Peyman
Journal:  Retina       Date:  2003-10       Impact factor: 4.256

9.  [Visual field defect after radial optic neurotomy].

Authors:  N Feltgen; J Herrmann; L Hansen
Journal:  Ophthalmologe       Date:  2005-08       Impact factor: 1.059

10.  A randomised prospective study on treatment of central retinal vein occlusion by isovolaemic haemodilution and photocoagulation.

Authors:  L L Hansen; P Danisevskis; H R Arntz; G Hövener; M Wiederholt
Journal:  Br J Ophthalmol       Date:  1985-02       Impact factor: 4.638

View more
  6 in total

Review 1.  Anti-vascular endothelial growth factor for macular edema secondary to central retinal vein occlusion.

Authors:  Tasanee Braithwaite; Afshan A Nanji; Paul B Greenberg
Journal:  Cochrane Database Syst Rev       Date:  2010-10-06

Review 2.  [Surgical treatments for retinal vein occlusion].

Authors:  N Feltgen; H Agostini; L Hansen
Journal:  Ophthalmologe       Date:  2007-04       Impact factor: 1.059

Review 3.  Anti-vascular endothelial growth factor for macular oedema secondary to central retinal vein occlusion.

Authors:  Tasanee Braithwaite; Afshan A Nanji; Kristina Lindsley; Paul B Greenberg
Journal:  Cochrane Database Syst Rev       Date:  2014-05-01

4.  Increased expression of angiogenic and inflammatory proteins in the vitreous of patients with ischemic central retinal vein occlusion.

Authors:  Christoph Ehlken; Bastian Grundel; Daniel Michels; Bernd Junker; Andreas Stahl; Günther Schlunck; Lutz L Hansen; Nicolas Feltgen; Gottfried Martin; Hansjürgen T Agostini; Amelie Pielen
Journal:  PLoS One       Date:  2015-05-15       Impact factor: 3.240

5.  Practical management of retinal vein occlusions.

Authors:  Carlo La Spina; Umberto De Benedetto; Maurizio Battaglia Parodi; Gabriel Coscas; Francesco Bandello
Journal:  Ophthalmol Ther       Date:  2012-08-09

6.  Radial optic neurotomy for central retinal vein occlusion.

Authors:  Ali-Reza Ramezani
Journal:  J Ophthalmic Vis Res       Date:  2009-04
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.